BioCentury | Jun 21, 2010
Clinical News

OXi4503 combretastatin A1 di-phosphate: Final Phase Ib data

...Symphony ViDA, which was formed by private equity firm Symphony Capital. OxiGene out-licensed the compound to Symphony ViDA...
BioCentury | Jul 27, 2009
Company News

OxiGene, Symphony ViDA deal

...OxiGene completed its previously announced acquisition of Symphony ViDA, which was formed by private equity firm Symphony...
...to account for the difference (see BioCentury, July 13). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Jul 13, 2009
Finance

Ebb & Flow

...week, Achillion shed $0.28 (17%) to $1.40. Redeploying ViDA By exercising its option to acquire Symphony ViDA...
...of cash and avoid a further buyback obligation of some $15 million. Symphony Capital formed Symphony ViDA...
...million. Last week's acquisition will add about $12.5 million, which is the cash remaining in Symphony ViDA...
BioCentury | Jul 13, 2009
Company News

OxiGene, Symphony ViDA deal

...OxiGene exercised its option to acquire Symphony ViDA in a stock deal. OxiGene gained the option last...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...
BioCentury | Jul 7, 2009
Company News

OxiGene to acquire Symphony ViDA

...OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN) exercised its option to acquire Symphony ViDA Inc. (Rockville, Md.) in a stock deal...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...
BioCentury | Jun 1, 2009
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase I data

...American Society of Clinical Oncology meeting in Orlando. Last October, OxiGene out-licensed the compound to Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Apr 13, 2009
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/IIa started

...carcinoma (HCC) or secondary hepatic tumor involvement. Last October, OxiGene out-licensed the compound to newco Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Dec 15, 2008
Company News

OxiGene deal

...million in cash. Symphony gained the warrant in its October deal with OxiGene to form Symphony ViDA Inc....
BioCentury | Oct 6, 2008
Finance

Ebb & Flow

...was valued at last Tuesday, the day before the deal was announced. The newco, called Symphony ViDA...
BioCentury | Oct 6, 2008
Company News

OxiGene deal

...OxiGene out-licensed Zybrestat fosbretabulin for ophthalmic indications and cancer compound OXi4503 to newco Symphony ViDA Inc. Symphony ViDA was...
...received an exclusive option to acquire Symphony ViDA. If the company does not exercise its option, Symphony ViDA...
...receive up to $1 million in OxiGene stock upon additional investment by Symphony Capital in Symphony ViDA...
Items per page:
1 - 10 of 11
BioCentury | Jun 21, 2010
Clinical News

OXi4503 combretastatin A1 di-phosphate: Final Phase Ib data

...Symphony ViDA, which was formed by private equity firm Symphony Capital. OxiGene out-licensed the compound to Symphony ViDA...
BioCentury | Jul 27, 2009
Company News

OxiGene, Symphony ViDA deal

...OxiGene completed its previously announced acquisition of Symphony ViDA, which was formed by private equity firm Symphony...
...to account for the difference (see BioCentury, July 13). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Jul 13, 2009
Finance

Ebb & Flow

...week, Achillion shed $0.28 (17%) to $1.40. Redeploying ViDA By exercising its option to acquire Symphony ViDA...
...of cash and avoid a further buyback obligation of some $15 million. Symphony Capital formed Symphony ViDA...
...million. Last week's acquisition will add about $12.5 million, which is the cash remaining in Symphony ViDA...
BioCentury | Jul 13, 2009
Company News

OxiGene, Symphony ViDA deal

...OxiGene exercised its option to acquire Symphony ViDA in a stock deal. OxiGene gained the option last...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...
BioCentury | Jul 7, 2009
Company News

OxiGene to acquire Symphony ViDA

...OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN) exercised its option to acquire Symphony ViDA Inc. (Rockville, Md.) in a stock deal...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...
BioCentury | Jun 1, 2009
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase I data

...American Society of Clinical Oncology meeting in Orlando. Last October, OxiGene out-licensed the compound to Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Apr 13, 2009
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/IIa started

...carcinoma (HCC) or secondary hepatic tumor involvement. Last October, OxiGene out-licensed the compound to newco Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....
BioCentury | Dec 15, 2008
Company News

OxiGene deal

...million in cash. Symphony gained the warrant in its October deal with OxiGene to form Symphony ViDA Inc....
BioCentury | Oct 6, 2008
Finance

Ebb & Flow

...was valued at last Tuesday, the day before the deal was announced. The newco, called Symphony ViDA...
BioCentury | Oct 6, 2008
Company News

OxiGene deal

...OxiGene out-licensed Zybrestat fosbretabulin for ophthalmic indications and cancer compound OXi4503 to newco Symphony ViDA Inc. Symphony ViDA was...
...received an exclusive option to acquire Symphony ViDA. If the company does not exercise its option, Symphony ViDA...
...receive up to $1 million in OxiGene stock upon additional investment by Symphony Capital in Symphony ViDA...
Items per page:
1 - 10 of 11